Analysts Issue Forecasts for MiMedx Group Q1 Earnings

MiMedx Group, Inc (NASDAQ:MDXG) – Investment analysts at Northland Securities issued their Q1 2026 earnings per share (EPS) estimates for MiMedx Group in a research note issued on Thursday, February 26th. Northland Securities analyst C. Byrnes forecasts that the company will post earnings per share of ($0.03) for the quarter. The consensus estimate for MiMedx Group’s current full-year earnings is $0.30 per share. Northland Securities also issued estimates for MiMedx Group’s Q3 2026 earnings at $0.03 EPS, Q4 2026 earnings at $0.04 EPS and FY2026 earnings at $0.04 EPS.

MiMedx Group (NASDAQ:MDXG) last announced its earnings results on Wednesday, February 25th. The company reported $0.14 earnings per share for the quarter, beating the consensus estimate of $0.09 by $0.05. The business had revenue of $118.10 million for the quarter, compared to the consensus estimate of $106.78 million. MiMedx Group had a net margin of 11.60% and a return on equity of 29.37%.

A number of other research analysts have also recently commented on MDXG. Citigroup began coverage on shares of MiMedx Group in a report on Monday, February 23rd. They issued a “market outperform” rating on the stock. Wall Street Zen lowered shares of MiMedx Group from a “strong-buy” rating to a “buy” rating in a research note on Saturday. Citizens Jmp started coverage on shares of MiMedx Group in a research note on Monday, February 23rd. They set a “market outperform” rating and a $10.00 price objective on the stock. Cantor Fitzgerald cut their target price on MiMedx Group from $12.00 to $8.00 and set an “overweight” rating on the stock in a research note on Tuesday, February 17th. Finally, UBS Group set a $10.00 price target on MiMedx Group in a research report on Monday, February 23rd. Five equities research analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the company. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $9.60.

MiMedx Group Trading Down 1.0%

Shares of NASDAQ MDXG opened at $4.89 on Monday. The business’s 50 day moving average price is $5.70 and its 200-day moving average price is $6.57. The company has a market cap of $726.51 million, a price-to-earnings ratio of 15.28 and a beta of 1.60. The company has a debt-to-equity ratio of 0.06, a quick ratio of 3.92 and a current ratio of 4.32. MiMedx Group has a fifty-two week low of $4.78 and a fifty-two week high of $8.46.

Hedge Funds Weigh In On MiMedx Group

Several large investors have recently made changes to their positions in the company. CWM LLC raised its holdings in MiMedx Group by 63.8% in the 2nd quarter. CWM LLC now owns 4,857 shares of the company’s stock worth $30,000 after purchasing an additional 1,892 shares during the period. PNC Financial Services Group Inc. lifted its stake in MiMedx Group by 1,808.4% in the 2nd quarter. PNC Financial Services Group Inc. now owns 7,500 shares of the company’s stock worth $46,000 after purchasing an additional 7,107 shares in the last quarter. Kemnay Advisory Services Inc. acquired a new position in MiMedx Group during the fourth quarter worth $48,000. State of Alaska Department of Revenue acquired a new position in shares of MiMedx Group during the 3rd quarter valued at about $54,000. Finally, Headlands Technologies LLC purchased a new stake in shares of MiMedx Group in the 2nd quarter valued at approximately $72,000. 79.15% of the stock is currently owned by institutional investors and hedge funds.

MiMedx Group Company Profile

MiMedx Group, Inc is a biopharmaceutical company focused on the development, manufacture and marketing of regenerative biomaterial products derived from human placental tissues. The company’s core mission centers on harnessing the extracellular matrix and growth factors within amniotic and chorionic membranes to support wound healing and surgical applications. MiMedx’s product line leverages proprietary purification processes designed to retain native tissue properties while ensuring sterility and safety.

MiMedx’s principal offerings include amnion/chorion allografts branded under names such as EpiFix® and AmnioFix®, which are indicated for the treatment of acute and chronic wounds—including diabetic foot ulcers, venous leg ulcers and surgical site repair.